Skip to main content

$201M (CAD) Exit for Bar Brand TRUBAR Reported Last Week by CPG Insider – Founded by Former NFL Player Brad Pyatt and His Wife

Acquisition highlights ETİ Gıda’s global expansion strategy and positions TRUBAR for accelerated growth in the better-for-you snacks category.TRUBAR: the plant-based protein bars VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) — According to CPG Insider, TRUBAR, a better-for-you bar brand under Simply Better Brands (TSE: TRBR), was announced last week to be acquired by ETİ Gıda in a $201 million (CAD) all-cash transaction. The deal, representing a 64% premium over TRUBAR’s previous closing share price, is expected to accelerate the brand’s growth across North America while expanding its global presence. The acquisition has reportedly been recommended by TRUBAR’s Board of Directors and Special Committee, which deemed the partnership in the company’s best interest. ETİ Gıda’s experience in scaling international consumer...

Continue reading

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker “PURR” NEW YORK and PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) — Hyperliquid Strategies Inc (“HSI” or the “Company”) and Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) (“Sonnet”) today announced the completion of the closing of the previously announced business combination among HSI, Sonnet and Rorschach I LLC (“Rorschach”), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC (“Atlas”), an affiliate of Paradigm Operations LP (“Paradigm”), and additional sponsors (all together, the “Sponsors”), which was approved by Sonnet’s stockholders on December 2, 2025. As a result of the closing, the Company will operate as a HYPE digital asset treasury reserve company, and Sonnet will...

Continue reading

Victory Tire & Auto Expands Presence in Rochester with Acquisition of Babcock Auto Care

New Partnership Brings Shared Values, Quality Service, and Community CommitmentVictory Tire & AutoVictory Tire & AutoROCHESTER, MN – [December 2, 2025], Dec. 02, 2025 (GLOBE NEWSWIRE) — Victory Tire & Auto, a trusted Minnesota name in complete auto repair since 1997, has announced the acquisition of Babcock Auto Care in Rochester, MN, marking its 24th shop in the state. Jeremy Babcock is a veteran of the automotive industry with over 30 years of experience. Jeremy and his wife, Jeanna Babcock, opened their first shop in Rochester in 2002 and have since grown a group of longstanding, loyal customers whom they proudly serve. Babcock Auto Care has earned its reputation for integrity, skilled service, and deep community ties, which is something Victory Tire & Auto also prides itself on. “From our...

Continue reading

All County Tire & Auto Expands Florida Presence with Acquisition of JC Automotive in St. Petersburg

ST. PETERSBURG, FL. – [December 2, 2026], Dec. 02, 2025 (GLOBE NEWSWIRE) — All County Tire & Auto, a trusted name in automotive repair across Florida, is proud to announce the acquisition of JC Automotive in St. Petersburg, Florida. The acquisition marks an exciting step in All County’s continued growth and commitment to providing high-quality automotive care throughout the region. Founded in 1988 by John Celona, JC Automotive has earned a strong reputation for its honesty, reliability, and dedication to customer satisfaction. “The most difficult decision in life is knowing the right time to sell your business,” said John Celona, founder of JC Automotive. “What mattered most to me was ensuring the employees who helped build this company over the years would continue to be valued and supported. When the opportunity came...

Continue reading

LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.

EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) — LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, today announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction. LAMY issued 62,223,000 restricted shares of its Common stock to finalize the deal, consolidating ownership of a highly promising preclinical oncology platform. Foundation Built on Exclusive, Worldwide Licensing The strategic acquisition reinforces Exousia Bio’s position as an innovator in the exosome space. The Company has secured two exclusive worldwide licenses for Exosome technology. These patented and patent-pending intellectual property rights...

Continue reading

LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.

EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) — LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, today announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction. LAMY issued 62,223,000 restricted shares of its Common stock to finalize the deal, consolidating ownership of a highly promising preclinical oncology platform. Foundation Built on Exclusive, Worldwide Licensing The strategic acquisition reinforces Exousia Bio’s position as an innovator in the exosome space. The Company has secured two exclusive worldwide licenses for Exosome technology. These patented and patent-pending intellectual property rights...

Continue reading

Otus Acquires MindPrint Learning to Create the Industry’s Most Comprehensive K-12 Student Profile Solution

With the addition of MindPrint’s student learning profile and strengths-based instruction strategies, Otus equips teachers with even more insights and tools to maximize student growth across all subjects.Otus, the leading K-12 platform for student assessment, data, and insights, announced today the acquisition of MindPrint Learning, a company renowned for helping educators understand how students learn best and tailor instruction to their iThe acquisition, advised by Tucker Capital on behalf of MindPrint Learning, follows a successful multiyear partnership and advances Otus’ mission to provide educators with a comprehensive, unified view of every student.CHICAGO, IL, Dec. 02, 2025 (GLOBE NEWSWIRE) — Otus, the leading K-12 platform for student assessment, data, and insights, announced today the acquisition of MindPrint...

Continue reading

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a non-binding term sheet (the “Term Sheet”) with an Israeli-based pioneering quantum computing bio data company focused on quantum-enabled clinical analytics (the “Target Company”). Pursuant to the Term Sheet, NeuroThera will acquire a 55% equity interest in the Target Company from certain selling shareholders of the Target Company (the “Selling Shareholders”), calculated on a post transaction fully diluted basis, in consideration for the...

Continue reading

Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc

PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that its stockholders approved, among other things, the proposed business combination with Hyperliquid Strategies Inc (“HSI”) and Rorschach I LLC at its special meeting of stockholders. The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission. About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human...

Continue reading

Quickbase Acquires Juiced Technologies

Acquisition will extend what’s possible in Quickbase and make it easier to get started with Juiced’s advanced add-ons BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) — Quickbase, the AI operations platform, today announced that it has acquired Juiced Technologies (“Juiced”), a long-standing partner specializing in developing and hosting Quickbase add-ons. The acquisition will extend Quickbase’s native functionality with Juiced’s advanced document formatting capabilities and e-signature, geomapping, and email-to-text features. For more than two decades, Juiced has developed a suite of advanced, customizable add-ons that not only complement the core Quickbase platform, but also extend what’s possible for Quickbase users—designed with an intuitive user experience in mind. Its portfolio, including JuicedSign, Exact Forms Plus, QB Maps, XL...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.